{'fraction_non_alphanumeric': 0.03647798742138365, 'fraction_numerical': 0.025157232704402517, 'mean_word_length': 5.170542635658915, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[The possible teratogenic effect of levamisole treatment during pregnancy].

The possible teratogenic effect of levamisole treatment during pregnancy. Levamisole (Decaris) is an anthelminthic agent. The teratogenic effect of levamisole was evaluated by the analysis of a large population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996. The mean gestational age was somewhat longer after levamisole treatment (adjusted t = 1.04; p = 0.30) while the mean birth weight was nearly similar in the two study groups (adjusted t = 0.36; p = 0.72). This first controlled case-control epidemiological study does not indicate a higher rate of congenital abnormalities in children born to mothers who had received oral levamisole treatment during pregnancy.